Brief: Exelixis Provides Regulatory Update Related To Supplemental New Drug Application For Cabozantinib

Exelixis

26/11/2024 22:29

Nov 26 (Reuters) - Exelixis Inc  EXEL.O :
    * EXELIXIS PROVIDES REGULATORY UPDATE RELATED TO
SUPPLEMENTAL NEW
DRUG APPLICATION FOR CABOZANTINIB (CABOMETYX®) FOR THE TREATMENT
OF PATIENTS WITH PREVIOUSLY TREATED ADVANCED NEUROENDOCRINE
TUMORS
    * EXELIXIS INC - FDA TO DISCUSS EXELIXIS' SNDA FOR CABOMETYX
IN
MARCH 2025

Source text:  ID:nBw3blNZya 
Further company coverage:  EXEL.O 

 ((Reuters.Briefs@thomsonreuters.com;))